ScholarIQanswers from OpenAlex & ORCID
Jayesh Desai
ResearcherPublications, citations & collaboration network
Jayesh Desai is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jayesh Desai have?
ScholarIQindexed works
Jayesh Desai has 640 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jayesh Desai have?
ScholarIQcitation count
Jayesh Desai has 30,131 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jayesh Desai?
ScholarIQh-index
Jayesh Desai has an h-index of 68 in OpenAlex.
What is the i10-index of Jayesh Desai?
ScholarIQi10-index
Jayesh Desai has an i10-index of 220 in OpenAlex.
What is the ORCID of Jayesh Desai?
ScholarIQorcid
The ORCID for Jayesh Desai is on the source record.
What is the OpenAlex record for Jayesh Desai?
ScholarIQopenalex
The OpenAlex for Jayesh Desai is on the source record.
What are the most-cited papers on Jayesh Desai?
ScholarIQmost cited works
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André
KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong, Marwan Fakih, John H. Strickler, Jayesh Desai, Gregory A. Durm, Geoffrey I. Shapiro, Gerald S. Falchook, Timothy Price, Adrian G. Sacher, Crystal S. Denlinger, Yung‐Jue Bang, Grace K. Dy, John C. Krauss, Yasutoshi Kuboki, James Kuo, Andrew L. Coveler, Keunchil Park, Tae Won Kim, Fabrice Barlési, Pamela N. Münster, Suresh S. Ramalingam, Timothy F. Burns, Funda Meric‐Bernstam, Haby Henary, Jude Ngang, Gataree Ngarmchamnanrith, June Myung Kim, Brett E. Houk, Jude Canon, J. Russell Lipford, Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero
Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer
Scott Kopetz, Jayesh Desai, Emily Chan, J. Randolph Hecht, Peter J. O’Dwyer, Dipen M. Maru, Van K. Morris, Filip Jankú, Arvind Dasari, Woonbok Chung, Jean‐Pierre J. Issa, Peter Gibbs, Brian P. James, Garth Powis, K. B. Nolop, Suman Bhattacharya, Leonard B. Saltz
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
Jeanne Tie, Isaac Kinde, Y. Wang, Hui‐Li Wong, Justin Kelvin Roebert, Michael Christie, Mark Tacey, Rachel Wong, Madhu Singh, Christos S. Karapetis, Jayesh Desai, Ben Tran, R L Strausberg, Luis A. Díaz, Nikolaos G. Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Peter Gibbs